BC Innovations | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

Researchers are finding new ways to monitor the immune system in hematologic diseases that could have implications for optimizing immuno-oncology therapies, according to BioCentury’s analysis of emerging targets at ASH 2019. In abstracts released ahead...
BC Innovations | Nov 21, 2019
Distillery Therapeutics

Drug-loaded lipid nanoparticles targeting tumor-associated myeloid cells for glioma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Targeting immunosuppressive tumor-associated myeloid cells (TAMCs) with drug-loaded anti-PD-L1 lipid nanoparticles could treat glioma, an indication in which TAMCs contribute up to 50% of the tumor mass. The nanoparticles,...
BC Innovations | Oct 24, 2019
Distillery Therapeutics

GCase activator reduces α-synuclein in mouse, patient-derived models of PD

DISEASE CATEGORY: Neurology INDICATION: Parkinson's disease (PD) Northwestern University researchers, including Lysosomal Therapeutics Inc. co-founder Dimitri Krainc, developed a small molecule GCase activator that could treat Parkinson’s disease. Mutations in GCase, a lysosomal enzyme, are...
BC Extra | Oct 23, 2019
Company News

Celiac data persuade Takeda to commit to Cour’s tolerance-inducing therapy

Now that Cour has demonstrated clinical proof of concept, Takeda has exercised its option to license the company’s first-in-class celiac disease therapy that induces tolerance. On Tuesday at the United European Gastroenterology Week meeting in...
BC Extra | Oct 17, 2019
Preclinical News

Oct. 17 Preclinical Quick Takes: Miromatrix, Mayo extend vascular function in liver graft scaffold; plus James Allison-MD Anderson, Northwestern and Eleusis

Extending vascular function in bioengineered liver graft scaffold  Miromatrix Inc. and Mayo Clinic researchers developed a way to vascularize bioengineered liver scaffolds that could maintain blood flow for more than a few days. Described in...
BC Extra | Jul 12, 2019
Company News

July 12 management tracks: Linus Lin joins Lilly’s Chorus; plus Ocular, Aptinyx

Eli Lilly and Co. (NYSE:LLY) named Linus Lin managing director of its Chorus R&D unit. He was previously VP and head of Lilly China Innovation and Partnerships. Eye disease company Ocular Therapeutix Inc. (NASDAQ:OCUL) hired...
BC Extra | May 17, 2019
Financial News

Actuate gets $21.7M to expand clinical testing of lead candidate

With its $21.7 million series B round, Actuate plans to expand clinical testing of its GSK3B inhibitor into Europe and advance its pediatric neuroblastoma program for the candidate. Kairos Ventures led the round, with participation...
BC Innovations | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BC Extra | Mar 20, 2019
Politics & Policy

Nature Comment: abandon dichotomous statistical thresholds

A trio of authors called for an end to the dichotomous use of "statistical significance" in a comment published Wednesday in Nature , which over 800 international researchers signed. The authors -- Valentin Amrhein, Sander Greenland...
BC Innovations | Mar 19, 2019
Distillery Therapeutics

ALK2 inhibition for diffuse intrinsic pontine glioma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Cell culture and mouse studies suggest inhibiting ALK2 could help treat diffuse intrinsic pontine glioma (DIPG) in patients harboring activating ALK2 mutations. In tumorspheres derived from an ALK2-mutant mouse...
Items per page:
1 - 10 of 250
BC Innovations | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

Researchers are finding new ways to monitor the immune system in hematologic diseases that could have implications for optimizing immuno-oncology therapies, according to BioCentury’s analysis of emerging targets at ASH 2019. In abstracts released ahead...
BC Innovations | Nov 21, 2019
Distillery Therapeutics

Drug-loaded lipid nanoparticles targeting tumor-associated myeloid cells for glioma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Targeting immunosuppressive tumor-associated myeloid cells (TAMCs) with drug-loaded anti-PD-L1 lipid nanoparticles could treat glioma, an indication in which TAMCs contribute up to 50% of the tumor mass. The nanoparticles,...
BC Innovations | Oct 24, 2019
Distillery Therapeutics

GCase activator reduces α-synuclein in mouse, patient-derived models of PD

DISEASE CATEGORY: Neurology INDICATION: Parkinson's disease (PD) Northwestern University researchers, including Lysosomal Therapeutics Inc. co-founder Dimitri Krainc, developed a small molecule GCase activator that could treat Parkinson’s disease. Mutations in GCase, a lysosomal enzyme, are...
BC Extra | Oct 23, 2019
Company News

Celiac data persuade Takeda to commit to Cour’s tolerance-inducing therapy

Now that Cour has demonstrated clinical proof of concept, Takeda has exercised its option to license the company’s first-in-class celiac disease therapy that induces tolerance. On Tuesday at the United European Gastroenterology Week meeting in...
BC Extra | Oct 17, 2019
Preclinical News

Oct. 17 Preclinical Quick Takes: Miromatrix, Mayo extend vascular function in liver graft scaffold; plus James Allison-MD Anderson, Northwestern and Eleusis

Extending vascular function in bioengineered liver graft scaffold  Miromatrix Inc. and Mayo Clinic researchers developed a way to vascularize bioengineered liver scaffolds that could maintain blood flow for more than a few days. Described in...
BC Extra | Jul 12, 2019
Company News

July 12 management tracks: Linus Lin joins Lilly’s Chorus; plus Ocular, Aptinyx

Eli Lilly and Co. (NYSE:LLY) named Linus Lin managing director of its Chorus R&D unit. He was previously VP and head of Lilly China Innovation and Partnerships. Eye disease company Ocular Therapeutix Inc. (NASDAQ:OCUL) hired...
BC Extra | May 17, 2019
Financial News

Actuate gets $21.7M to expand clinical testing of lead candidate

With its $21.7 million series B round, Actuate plans to expand clinical testing of its GSK3B inhibitor into Europe and advance its pediatric neuroblastoma program for the candidate. Kairos Ventures led the round, with participation...
BC Innovations | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BC Extra | Mar 20, 2019
Politics & Policy

Nature Comment: abandon dichotomous statistical thresholds

A trio of authors called for an end to the dichotomous use of "statistical significance" in a comment published Wednesday in Nature , which over 800 international researchers signed. The authors -- Valentin Amrhein, Sander Greenland...
BC Innovations | Mar 19, 2019
Distillery Therapeutics

ALK2 inhibition for diffuse intrinsic pontine glioma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Cell culture and mouse studies suggest inhibiting ALK2 could help treat diffuse intrinsic pontine glioma (DIPG) in patients harboring activating ALK2 mutations. In tumorspheres derived from an ALK2-mutant mouse...
Items per page:
1 - 10 of 250